Guerbet

Guerbet to Spotlight Diagnostic Solutions at the 2023 Radiological Society of North America (RSNA) Scientific Assembly and Annual Meeting

Retrieved on: 
星期一, 十一月 27, 2023

PRINCETON, N.J., Nov. 27, 2023 /PRNewswire/ -- Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced today its schedule of activities at the 2023 Radiological Society of North America (RSNA) Scientific Assembly and Annual Meeting from November 26-30 in Chicago, IL. In addition to the Guerbet exhibit (booth #1711), the company will be presenting safety data in an abstract titled "Safety of gadopiclenol for magnetic resonance imaging (MRI): a pooled analysis of eight studies." The session number W3-STCE1, will be presented as a scientific session on Wednesday, November 29 at 10:00-10:30 a.m. CST.

Key Points: 
  • Jeffrey H Maki, MD, PhD, Professor of Radiology and Director of MRI at the University of Colorado in Denver will be presenting "Relaxation properties of GBCAs In Vitro, in human blood – their unique behavior might surprise you" at 1:00 p.m. CST on Monday, November 27th.
  • This presentation, which will take place in the RSNA Innovation Theater Exhibitor Pavillion in the South Hall, is based on a study done to measure T1 and T2 relaxivity In Vitro, in human blood.
  • In addition to showcasing diagnostic and interventional solutions, Guerbet will also feature its digital and AI software-based products that help to close the loop with the smart connectivity between monitoring and reporting.
  • Products that will be featured include:
    Contrast & Care®, an injection data management solution that enables imaging centers to collect, archive, examine, and share injection data, including data on contrast products, adverse events, injector activity, information on estimated glomerular filtration rate, and other risk factors before a clinical exam
    Optistar™ Elite, a dual head contrast delivery system with an ultrasonic motor that makes it non-magnetic, built for long lasting performance and now has the new Fractional Dosing capabilities

Hospital-based procedures drive CT procedure volume growth

Retrieved on: 
星期一, 十一月 13, 2023

ARLINGTON, Va., Nov. 13, 2023 /PRNewswire-PRWeb/ -- CT procedure volumes increased 9.1% from 2022 to 2023, according to IMV's recently published 2023 CT Market Outlook Report. While both hospital and non-hospital CT procedure volumes increased, hospital volumes increased year-over-year by almost 10% while, non-hospital volumes increased at just over 6%.‥

Key Points: 
  • ARLINGTON, Va., Nov. 13, 2023 /PRNewswire-PRWeb/ -- CT procedure volumes increased 9.1% from 2022 to 2023, according to IMV's recently published 2023 CT Market Outlook Report .
  • While both hospital and non-hospital CT procedure volumes increased, hospital volumes increased year-over-year by almost 10% while, non-hospital volumes increased at just over 6%.‥
    Looking ahead into 2024, 72% of CT sites surveyed anticipate that their 2024 CT procedures will increase compared to 2023, while 23% expect them to stay the same and just 1% of sites anticipate a decrease.
  • One likely cause of the increase, with 60% of survey respondents rating 4 or 5 out of 5, is due to some procedures shifting from other imaging modalities to CT, according to the report.
  • Overall, the report found that in 2023, an average of two CT technologists are involved with performing and preparing patients for CT exams on each scanner in their facility.

Guerbet to Spotlight Diagnostic and Interventional Solutions at the 2023 Radiological Society of North America (RSNA) Scientific Assembly and Annual Meeting

Retrieved on: 
星期四, 十一月 2, 2023

PRINCETON, N.J., Nov. 2, 2023 /PRNewswire/ -- Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced today its schedule of activities at the 2023 Radiological Society of North America (RSNA) Scientific Assembly and Annual Meeting from November 26-30 in Chicago, IL. In addition to the Guerbet exhibit (booth #1711), the company will be presenting safety data in an abstract titled "Safety of gadopiclenol for magnetic resonance imaging (MRI): a pooled analysis of eight studies." The session number W3-STCE1, will be presented as a scientific session on Wednesday, November 29 at 10:00-10:30 a.m. CST.

Key Points: 
  • Jeffrey H Maki, MD, PhD, Professor of Radiology and Director of MRI at the University of Colorado in Denver will be presenting "Relaxation properties of GBCAs In Vitro, in human blood – their unique behavior might surprise you" at 1:00 p.m. CST on Monday, November 27th.
  • This presentation, which will take place in the RSNA Innovation Theater Exhibitor Pavillion in the South Hall, is based on a study done to measure T1 and T2 relaxivity In Vitro, in human blood.
  • In addition to showcasing diagnostic and interventional solutions, Guerbet will also feature its digital and AI software-based products that help to close the loop with the smart connectivity between monitoring and reporting.
  • Products that will be featured include:
    Contrast & Care®, an injection data management solution that enables imaging centers to collect, archive, examine, and share injection data, including data on contrast products, adverse events, injector activity, information on estimated glomerular filtration rate, and other risk factors before a clinical exam
    Optistar™ Elite, a dual head contrast delivery system with an ultrasonic motor that makes it non-magnetic, built for long lasting performance and now has the new Fractional Dosing capabilities

Guerbet: 2023 half-year results

Retrieved on: 
星期三, 九月 20, 2023

As indicated when the annual results were published, Guerbet's 2023 operational profitability is subject to a context in which costs are rising more sharply than in the previous fiscal year.

Key Points: 
  • As indicated when the annual results were published, Guerbet's 2023 operational profitability is subject to a context in which costs are rising more sharply than in the previous fiscal year.
  • As of 30 June 2023, the Group's operating income was €10.3 million, compared to €16.9 million one year earlier.
  • In terms of profitability, inflationary pressures (in particular for iodine) will continue to be felt in the second half of 2023.
  • In this context, Guerbet confirms that it anticipates revenue growth of more than 5% on a like-for-like basis and at CER in 2023.

Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Company’s Tests

Retrieved on: 
星期四, 九月 7, 2023

Veracyte, Inc. (Nasdaq: VCYT) announced that Marie-Claire Taine, Ph.D., will join Veracyte as general manager of the company’s in vitro diagnostics (IVD) Business Unit, based in Marseille, France.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) announced that Marie-Claire Taine, Ph.D., will join Veracyte as general manager of the company’s in vitro diagnostics (IVD) Business Unit, based in Marseille, France.
  • She will lead the global expansion of Veracyte’s tests and will also serve as site lead for the company’s Marseille operations.
  • View the full release here: https://www.businesswire.com/news/home/20230907364591/en/
    Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit.
  • Taine’s extensive international management experience and commercial leadership make her the ideal person to lead the global expansion of Veracyte’s IVD test menu.

Guerbet: First-half 2023 revenue

Retrieved on: 
星期四, 七月 20, 2023

Diagnostic Imaging revenue in the first half of 2023 increased 3.3% at CER (+2.5% at current exchange rates).

Key Points: 
  • Diagnostic Imaging revenue in the first half of 2023 increased 3.3% at CER (+2.5% at current exchange rates).
  • It should be noted that X-ray revenue now includes the revenue of the company Intrasense, consolidated as of January 2023.
  • Intrasense (€3.8 million in revenue in 2022) joined the Group to accelerate its strategy for marketing AI technologies from third parties.
  • Overall, and as indicated in the reporting of full-year results in March, revenue growth in the second half of 2023 is expected to be stronger than in the first half.

Guerbet: Guerbet wins PI-CAI Grand Challenge on detection of prostate cancer

Retrieved on: 
星期一, 七月 17, 2023

The second male cancer according to the WHO, prostate cancer, with 1.4 million new cases each year worldwide, accounts for 6.8% of male cancer-related deaths (350,000 deaths per year).

Key Points: 
  • The second male cancer according to the WHO, prostate cancer, with 1.4 million new cases each year worldwide, accounts for 6.8% of male cancer-related deaths (350,000 deaths per year).
  • Magnetic resonance imaging (MRI) plays an increasingly important role in the early diagnosis of prostate cancer.
  • By training artificial intelligence on these data, it becomes possible to create a model capable of detecting the early signs of prostate cancer.
  • The PI-CAI Grand Challenge, launched in November 2022 on the detection of prostate cancer, aims to encourage technological advances in early diagnosis and accurate detection of prostate cancer and to evaluate the performance of participants' artificial intelligence algorithms.

Applied Radiology and Guerbet Launch 'Elucirem (Gadopiclenol) injection | The Reveal Image Challenge'

Retrieved on: 
星期二, 五月 23, 2023

PRINCETON, N.J., May 23, 2023 /PRNewswire/ -- Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced today a partnership with Applied Radiology, the leading peer reviewed radiology publication in the United States, where they will introduce "Elucirem | The Reveal Image Challenge. The program provides MR imaging professionals with an opportunity to reveal their MR imaging potential and to share their MRI images using Elucirem™ (gadopiclenol) injection. MRI imaging using Elucirem™ and supporting case information can be submitted on a secure image portal at appliedradiology.com/reveal and will be accepted until starting in May-Dec 2023.

Key Points: 
  • The program provides MR imaging professionals with an opportunity to reveal their MR imaging potential and to share their MRI images using Elucirem™ (gadopiclenol) injection.
  • A winning image will be selected each month by a review committee, including MRI thought leaders and educators, Applied Radiology board members and Guerbet associates.
  • Throughout the challenge, winning images will be featured on the Applied Radiology website and social media platforms.
  • "This partnership with Applied Radiology was conceived as we began to see some extraordinary images coming from the radiology community with the use Elucirem™," said David Hale, Chief Executive Officer at Guerbet.

U.S MR (Magnetic Resonance) Market - 2022 Report Reveals that 53% of MR Sites Were Considering the Purchase of a New Scanner Between 2022 and 2025 - ResearchAndMarkets.com

Retrieved on: 
星期四, 四月 6, 2023

In addition, the report covers installed base and purchase plan information for MR contrast media and power injectors.

Key Points: 
  • In addition, the report covers installed base and purchase plan information for MR contrast media and power injectors.
  • To monitor key industry trends, results from this 2022 MR Market Outlook Report are compared to previous MR market reports.
  • Three-quarters of MR sites in the U.S. anticipate that their 2022 procedure volume will be higher in 2022 than in 2021, according to the analyst’s 2022 MR Market Outlook Report.
  • At the time of the 2022 survey, 53% of MR sites were considering the purchase of a new scanner between 2022 and 2025.

Guerbet Announces Commercial Launch and First Patient Dosing of Elucirem™ (Gadopiclenol) Injection, a Novel New Macrocyclic GBCA for Use in Contrast-Enhanced Magnetic Resonance Imaging (MRI)

Retrieved on: 
星期一, 二月 13, 2023

PRINCETON, N.J., Feb. 13, 2023 /PRNewswire/ -- Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced today the commercial launch and dosing of the first patient with Elucirem™ (gadopiclenol) injection following FDA approval in 2022. This next generation GBCA from Guerbet, highly stable macrocyclic gadolinium-based contrast agent (GBCA), has the highest relaxivity in its class for magnetic resonance imaging (MRI) and is indicated for use in adults and children aged 2 years and older.1,4 Elucirem™ requires only half the gadolinium dose of conventional non-specific GBCAs, addressing practitioners' concerns about gadolinium exposure.2,3 The first dosing took place at the Hospital of the University of Pennsylvania in Philadelphia, PA.

Key Points: 
  • Elucirem™ requires only half the gadolinium dose of conventional non-specific GBCAs, addressing practitioners' concerns about gadolinium exposure.
  • 2,3
    PRINCETON, N.J., Feb. 13, 2023 /PRNewswire/ -- Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced today the commercial launch and dosing of the first patient with Elucirem™ (gadopiclenol) injection following FDA approval in 2022.
  • This milestone is the first of many for this novel new product, which has proven to be a promising step forward for the scientific and digital imaging community," said David Hale, Chief Executive Officer at Guerbet.
  • Elucirem is manufactured by Liebel-Flarsheim™ Company LLC, a Guerbet Group company, in Raleigh, North Carolina.